Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors.
- 4 January 2002
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 66 (3) , 299-303
- https://doi.org/10.1002/jmv.2145
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Prevalence and Conditions of Selection of E44D/A and V118I Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in Clinical PracticeAntimicrobial Agents and Chemotherapy, 2001
- A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184VAntimicrobial Agents and Chemotherapy, 2000
- Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (1592U89) after Monotherapy and Combination TherapyThe Journal of Infectious Diseases, 2000
- Antiretroviral Therapy in AdultsJAMA, 2000
- Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudineAIDS, 2000
- Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosineJournal of Medical Virology, 1999
- Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell cultureAntimicrobial Agents and Chemotherapy, 1994
- Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistanceJournal of General Virology, 1994
- Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidineAntimicrobial Agents and Chemotherapy, 1992
- Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)Science, 1989